Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

NCT ID: NCT01050439

Last Updated: 2015-04-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-11-30
• Study Completion Date: 2011-04-30

Brief Summary

Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.

Detailed Description

This is a non-randomized study to determine the tolerability and degree of engraftment of unrelated matched donor allogeneic stem cell transplantation with either myeloablative or reduced intensity conditioning in patients with selected malignant and non malignant disorders. Patients will receive one of either full intensity or reduced intensity regimen based on the patient's disease status, organ function and performance and determined by the PI.

Conditions

Leukemia; Lymphoma; Bone Marrow Failure Syndromes; Immunodeficiencies; Histiocytosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

UDAlloSCT + Therapy

This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.

Group Type: EXPERIMENTAL

UDAlloSCT

Intervention Type: PROCEDURE

unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)

Therapy

Intervention Type: OTHER

Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))

Interventions

UDAlloSCT

unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)

Intervention Type: PROCEDURE

Therapy

Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR > 40 ml/min/m2 or > 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range.
• Adequate liver function defined as: total bilirubin < 2.5 x normal; or SGOT (AST) or SGPT (ALT) < 5.0 x normal.
• Adequate cardiac function defined as: shortening fraction of > 25% by echocardiogram, or ejection fraction of > 40% by radionuclide angiogram or echocardiogram.
• Adequate pulmonary function defined as: DLCO > 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% in room air.
• Diseases:

• CML (CP, AP or BC)
• AML/MDS/JCML
• ALL
• Lymphoma (Hodgkin's and non-Hodgkin's)
• Non-malignant disorders
• Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible:

• Severe Aplastic Anemia:
• Fanconi Anemia
• Severe Congenital Neutropenia (Kostmann's Syndrome)
• Amegakaryocytic Thrombocytopenia
• Diamond-Blackfan Anemia
• Infantile Osteopetrosis
• Schwachman-Diamond Syndrome
• Dyskeratosis Congenita
• Other bone marrow failure syndromes at discretion of Principal Investigator
• Immunodeficiencies:

• SCIDS, all subtypes
• Combined Immunodeficiency Syndrome
• Wiskott-Aldrich syndrome
• Chronic Granulomatous Disease
• Chediak-Higashi Syndrome
• Leukocyte Adhesion Deficiency
• Other immunodeficiencies at discretion of Principal Investigator
• Inborn Errors of Metabolism (IEOM):

• Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator
• For X-ALD patients greater than 5 years of age, IQ > 80 is required. For other patients greater than 5 years of age, IQ > 70 is required.
• For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation.
• Histiocytosis:

• Hemophagocytic Lymphohistiocytosis (HLH)
• Familial Erythrophagocytic Lymphohistiocytosis
• Langerhans Cell Histiocytosis
• Malignant Histiocytosis
• Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator.

Exclusion Criteria

• Women who are pregnant and/or breast feeding are ineligible

• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mitchell S Cairo, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Columbia University Medical Center

New York, New York, United States

Countries

United States

Other Identifiers

CHNY-02-516

Identifier Type: OTHER

Identifier Source: secondary_id

AAAB3095

Identifier Type: -

Identifier Source: org_study_id